Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bppr consulting - lidocaine (lignocaine) hydrochloride monohydrate -

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 100mg;  ;   - film coated tablet - 100 mg - active: lacosamide 100mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry yellow 85f38040 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 150mg;  ;   - film coated tablet - 150 mg - active: lacosamide 150mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry tan 85f27043 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 200mg;  ;   - film coated tablet - 200 mg - active: lacosamide 200mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry blue 85f30675 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 50mg;  ;   - film coated tablet - 50 mg - active: lacosamide 50mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry purple 85f20249 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 10 mg/ml - solution for injection - 200 mg/20ml - active: lacosamide 10 mg/ml excipient: hydrochloric acid sodium chloride water for injection - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. vimpat (lacosamide) injection for intravenous infusion is indicated when oral administration is temporarily not feasible. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamide - epilepsies, partial - antiepileptics, - lacosamide ucb is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 10 mg/ml;   - oral solution - 10 mg/ml - active: lacosamide 10 mg/ml   excipient: acesulfame potassium carmellose sodium citric acid glycerol macrogol 4000 mask flavour 501521 t purified water sodium chloride sodium methyl hydroxybenzoate sorbitol as crystallizing liquid strawberry flavour 501440t - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bppr consulting - naloxone hydrochloride dihydrate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bppr consulting - naloxone hydrochloride dihydrate -